[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"disseminated-intravascular-coagulation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:disseminated-intravascular-coagulation":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,67,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100610980","role-of-fibrinolytic-activity-in-neoplastic-pathologies-complicated-by-coagulopathy-100610980",false,"NCT07234630","Role of Fibrinolytic Activity in Neoplastic Pathologies Complicated by Coagulopathy","NEO-COAG","Inclusion Criteria:\n\nFor all groups:\n\n* Age \\> 18 years\n* Patient hospitalized in Emergency Medicine, Intensive Care Medicine or Hematology\u002FOncology Intensive Care, Hematology\u002FOncology Service or Hepatobiliary and Digestive Surgery Service\n* Coagulopathy defined by the combination of thrombocytopenia (\\\u003C 100 G\u002FL) and increased INR (\\>1.2)\n\nGroup 1: Malignant hemopathies with large tumor masses:\n\n* Acute myeloblastic or lymphoblastic leukemia with leukocyte count (or blasts) \\>50G\u002FL in peripheral blood, or\n* Lymphoma documented by tissue biopsy, with biological tumor lysis syndrome, diagnosed according to Cairo and Bishop criteria (3).\n\nGroup 2: Locally advanced or metastatic solid tumors with DIC:\n\n* Prostatic adenocarcinoma\n* Malignant pancreatic or biliary tract tumor (cholangiocarcinoma),\n* Scheduled complex hepatobiliary carcinological surgery,\n* Metastatic adenocarcinoma of the digestive tract.\n\nGroup 3: Control group (free of neoplastic pathology, with well-studied coagulopathy): Septic shock\n\nExclusion Criteria:\n\n* Patient under protective supervision (guardianship or curatorship)\n* Pregnant women\n* Patients weighing less than 50 kg\n* Patient already included in the study\n* Congenital hemostasis disorders\n* Active bleeding at the time of inclusion\n* Patient with cirrhosis\n* Patients receiving curative anticoagulation therapy\n* Patients with a spontaneous INR \\> 1.2 in a previous blood test in a context of fibrinolytic insufficiency\n* Each group is exclusive of the other, for example :\n\nFor Group 1 (Neoplastic pathologies): Presence of documented sepsis at the time of inclusion","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","OBSERVATIONAL","The aim of this research is to measure fibrinolytic activity in neoplastic pathologies in order to provide preliminary data on which to base a future, larger-scale study to determine predictive markers of complication in order to improve patient management.\n\nPrimary purpose: measure plasminogen concentration on day 1 in subjects diagnosed with malignant hematological disease, solid tumors, or septic shock, with coagulopathy.\n\nSecondary purpose:\n\n* Estimate the difference in plasminogen concentration at D1 in patients with coagulopathy between subjects with a diagnosis of haematological malignancy and those with solid tumor\n* Estimate the difference in plasminogen concentration at D1 in patients with coagulopathy between subjects with a diagnosis of haematological malignancy and those with septic shock\n* Estimate the difference in plasminogen concentration on Day 1 in patients with coagulopathy between subjects with a diagnosis of solid tumor and those with septic shock.\n\nIn the 3 groups, subjects with a diagnosis of haematological malignancy, solid tumor, septic shock, presenting with coagulopathy:\n\n* Evaluate the correlation between the concentration of circulating plasminogen active on Day 1 and the occurrence of a bleeding complication within 28 days of admission to critical care.\n* Evaluate the correlation between the concentration of circulating plasminogen active on Day 1 and the occurrence of a thrombotic complication, within 28 days of admission to critical care.\n* Evaluate the predictive performance of circulating active plasminogen concentration on Day 1 in the need for extra renal purification within 28 days of admission to critical care.\n* Estimate the differences at each time point (D1, D3, D7) in haemostasis markers and markers of fibrinolytic activity and its regulation.\n\nAssess the link between fibrinolytic activity and :\n\n* The diagnosis of disseminated intravascular coagulation (DIC),\n* The risk of haemorrhage\n* Risk of organ failures\n* Thrombotic risk\n* Risk of organ failure\n* Neutrophile activation and circulating NETs levels",[24,25,26],"Hematologic Neoplasms","Solid Tumor Metastatic Cancer Advanced Cancer","Disseminated Intravascular Coagulation","NOT_YET_RECRUITING","2025-12-09",{"date":30,"type":31},"2025-12-10","ACTUAL",{"date":33,"type":20},"2026-01",{"date":35,"type":20},"2028-02",{"name":37,"class":38},"University Hospital, Strasbourg, France","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":39},"100543997","disseminated-intravascular-coagulation-dic-score-and-organ-dysfunction-in-septic-shock-patients-100543997","NCT06363149","Disseminated Intravascular Coagulation (DIC) Score and Organ Dysfunction in Septic Shock Patients","Effect of Disseminated Intravascular Coagulation (DIC) Score Changes on Organ Dysfunction in Septic Shock Patients","Inclusion Criteria:\n\n* Adult ICU patients having septic shock as defined by Sepsis -3 definition requiring vasopressor for at least 12 hours duration will be considered.\n\nExclusion Criteria:\n\n* Patient having septic shock duration either less than 12 hours or more than 24 hours at the time of the inclusion\n* Age less than 18 years or more than 65 years\n* Expected survival less than 72 hours\n* Caregiver refused for the consent to participate in the study","65 Years",{"count":49,"type":20},60,"Septic shock is common complication in patients with critical illnesses, with higher incidence in low and medium income countries like ours. Disseminated intravascular coagulation (DIC) is also common in patients presenting to intensive care units. Further DIC is common coexisting condition seen in many patients presenting with sepsis and septic shock.\n\nBoth DIC and septic shock individually are associated with very high mortality and morbidity and coexistence of both increase risk manifold. Organ dysfunction is a complication of both septic shock and DIC individually and in presence of coexistence risk further multiply. DIC scoring of every patient at risk as in patients presenting with septic shock help us to predict about patients having more chances to convert to overt DIC.\n\nUnderstanding effects of DIC on organ dysfunction in septic shock patients can help to prognosticate and guide towards early intervention. Also, there is paucity of literature on effect of DIC score changes on organ dysfunction in patients with septic shock.",[52,26],"Septic Shock",[54,55],"Critical Illnesses","Multiple Organ Dysfunction Syndrome","RECRUITING","2025-05-13",{"date":59,"type":31},"2025-05-16",{"date":61,"type":31},"2024-04-12",{"date":63,"type":20},"2025-09",{"name":65,"class":66},"Sanjay Gandhi Postgraduate Institute of Medical Sciences","OTHER_GOV",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":74,"targetDuration":76,"studyType":21,"phases":4,"briefSummary":77,"conditions":78,"keywords":94,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100572008","longitudinal-cohort-of-thrombosis-and-hemostasis-diseases-100572008","NCT06727669","Longitudinal Cohort of Thrombosis and Hemostasis Diseases","Inclusion Criteria:\n\n* Patients who were diagnosed as thrombosis and hemostasis diseases.\n\nExclusion Criteria:\n\n* Long-term follow-up information for patients is not available for any reason, such as not being available or having a serious concomitant disease.\n* Patients with alcohol and drug addictions or mental illness affect their ability to comply with study requirements.\n* According to the investigator, there are conditions that may endanger the patient's safety or affect his\u002Fher compliance.",true,{"count":75,"type":20},3000,"5 Years","This is a multicenter, prospective, longitudinal, observational cohort study to investigate thrombosis and hemostasis diseases in Chinese patients. This study will collect basic information, diagnostic and treatment information, as well as medical expense information of patients from medical records.The incidence and risk factors of thrombosis and hemostasis diseases, the treatment methods, prognosis and medical expenses of these patients in China will be analyzed. The study will use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.",[79,80,81,26,82,83,84,85,86,87,88,89,90,91,92,93],"Immune Thrombocytopenia","Thrombotic Thrombocytopenic Purpura","Hemophilia A, Acquired","Thrombophilia","Deep Vein Thrombosis","Pulmonary Embolism","Thrombotic Microangiopathies","Coagulation Factor Deficiency","Hemophilia A","Hemophilia B","Hemophilia B, Acquired","Platelet Dysfunction","Arterial Thromboembolism","Bleeding Disorder","Thrombosis",[93,95],"Hemostasis","2024-12-05",{"date":98,"type":31},"2024-12-11",{"date":100,"type":31},"2024-11-01",{"date":102,"type":20},"2030-12-31",{"name":104,"class":38},"Peking University People's Hospital",5,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":4},"100564261","predictive-value-of-scoring-system-in-neonates-with-disseminated-intravascular-coagulation-100564261","NCT06626880","Predictive Value of Scoring System in Neonates with Disseminated Intravascular Coagulation","Inclusion Criteria:\n\n1. age at enrollment from the first day of life to 28 days of life.\n2. Neonates diagnosed as DIC.\n\nExclusion Criteria:\n\n1. Neonates born to mothers with ITP.\n2. Autoimmune thrombocytopenic patients.","28 Days",{"count":114,"type":20},43,"The aims of this study were to investigate underlying diseases associated with neonatal DIC diagnosed on the first 28 days of life, and whether DIC score could predict mortality in neonates.",[26,117],"Neonates","2024-10-02",{"date":120,"type":31},"2024-10-04",{"date":122,"type":20},"2025-01-01",{"date":124,"type":20},"2026-03-29",{"name":126,"class":38},"Assiut University"]